These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36242517)

  • 1. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma.
    Kapelanski-Lamoureux A; Chen Z; Gao ZH; Deng R; Lazaris A; Lebeaupin C; Giles L; Malhotra J; Yong J; Zou C; de Jong YP; Metrakos P; Herzog RW; Kaufman RJ
    Mol Ther; 2022 Dec; 30(12):3542-3551. PubMed ID: 36242517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular stress and coagulation factor production: when more is not necessarily better.
    Chen Z; Herzog RW; Kaufman RJ
    J Thromb Haemost; 2023 Dec; 21(12):3329-3341. PubMed ID: 37839613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
    Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
    JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.
    Cao W; Dong B; Horling F; Firrman JA; Lengler J; Klugmann M; de la Rosa M; Wu W; Wang Q; Wei H; Moore AR; Roberts SA; Booth CJ; Hoellriegl W; Li D; Konkle B; Miao C; Reipert BM; Scheiflinger F; Rottensteiner H; Xiao W
    Mol Ther Methods Clin Dev; 2020 Dec; 19():486-495. PubMed ID: 33313336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential for cellular stress response to hepatic factor VIII expression from AAV vector.
    Zolotukhin I; Markusic DM; Palaschak B; Hoffman BE; Srikanthan MA; Herzog RW
    Mol Ther Methods Clin Dev; 2016; 3():16063. PubMed ID: 27738644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codon optimization of human factor VIII cDNAs leads to high-level expression.
    Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
    Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.
    Roy S; Shirley PS; Connelly S; Andrews JL; Kayda DB; Gardner JM; Kaleko M
    Haemophilia; 1999 Sep; 5(5):340-8. PubMed ID: 10583516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and characterization of a codon-optimized blood coagulation factor VIII.
    Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
    J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice.
    Connelly S; Smith TA; Dhir G; Gardner JM; Mehaffey MG; Zaret KS; McClelland A; Kaleko M
    Hum Gene Ther; 1995 Feb; 6(2):185-93. PubMed ID: 7537539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
    Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
    Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
    Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
    Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioengineering of coagulation factor VIII for improved secretion.
    Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
    Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.